Objective
To study pregnancy outcomes in women with coarctation of the aorta (CoA) and associations to hypertensive disorders of pregnancy.
Background
Maternal morbidity and mortality are higher in women with heart disease and preeclampsia. Chronic hypertension, frequently encountered in CoA, is a risk factor for preeclampsia.
Methods
Clinical data from the National Unit for Pregnancy and Heart Disease database was reviewed for pregnant women with CoA from 2008 to 2021. The primary outcome was hypertensive pregnancy disorders. The secondary outcomes were other cardiovascular, obstetric, and fetal complications.
Results
Seventy-six patients were included, with a total of eighty-seven pregnancies. Seventeen (20%) patients were treated for chronic hypertension before pregnancy. Fifteen (20%) patients developed preeclampsia, and five (7%) had pregnancy-induced hypertension. Major adverse cardiac events developed in four (5%) patients, with no maternal or fetal mortality. Maternal age at first pregnancy (Odds ratio (OR) 1.37), BMI before first pregnancy (OR 1.77) and using ASA from the first trimester (OR 0.22) was statistically significantly associated with preeclampsia. At follow-up (median) eight years after pregnancy, twenty-nine (38%) patients had antihypertensive treatment, an increase of 16% compared to pre-pregnancy. Five (7%) patients had progression of aorta ascendens dilatation to >40mm, seven (9%) had an upper to lower systolic blood pressure BP gradient >20 mmHg, and six (8%) had received CoA reintervention.
Conclusions
Preeclampsia occurred in 20% of women with CoA in their first pregnancy. All preeclamptic patients received adequate antihypertensive treatment. All CoA patients was provided multidisciplinary management, including cardiologic follow-up, to optimize maternal-fetal outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.